Evidence map›Paper›PMID 25545414›Full record

ArticleJournal of proteomics2015

Plasmodium vivax trophozoite-stage proteomes.

D C Anderson, Stacey A Lapp, Sheila Akinyi, Esmeralda V S Meyer, John W Barnwell, Cindy Korir-Morrison, Mary R Galinski

Open access · greenAbstract read
In one paragraph

Article in Journal of proteomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. An epigrammatic status of the 'RSC medicinal chemistry · 2020
    Review
  8. Review
  9. Open forum infectious diseases · 2019
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Frontiers in cellular and infection microbiology · 2018
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Severe malaria: what's new on the pathogenesis front?International journal for parasitology · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

D C AndersonCenter for Cancer and Metabolism, SRI International, Harrisonburg, VA 22802, United States. Electronic address: dave.anderson@sri.com.
Stacey A LappEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, United States.
Sheila AkinyiEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, United States.
Esmeralda V S MeyerEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, United States.
John W BarnwellMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States.
Cindy Korir-MorrisonEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, United States.
Mary R GalinskiEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, United States; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, United States.
Emory University · USDivision of Parasitic Diseases and Malaria · USSRI International · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0M
MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENSR01AI024710 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GALINSKI, MARY R · 1987 to 2012
$5.2M
NCRR NIH HHS P51 RR000165NCRR NIH HHS P51RR000165NIAID NIH HHS HHSN272201200031CNIAID NIH HHS R01 AI024710NIAID NIH HHS R01-AI24710NIH HHS OD P51OD011132NIH HHS P51 OD011132PHS HHS HHSN272201200031C
6 · The paper itself

Abstract

Plasmodium vivax is the causative infectious agent of 80-300 million annual cases of malaria. Many aspects of this parasite's biology remain unknown. To further elucidate the interaction of P. vivax with its Saimiri boliviensis host, we obtained detailed proteomes of infected red blood cells, representing the trophozoite-enriched stage of development. Data from two of three biological replicate proteomes, emphasized here, were analyzed using five search engines, which enhanced identifications and resulted in the most comprehensive P. vivax proteomes to date, with 1375 P. vivax and 3209 S. boliviensis identified proteins. Ribosome subunit proteins were noted for both P. vivax and S. boliviensis, consistent with P. vivax's known reticulocyte host-cell specificity. A majority of the host and pathogen proteins identified belong to specific functional categories, and several parasite gene families, while 33% of the P. vivax proteins have no reported function. Hemoglobin was significantly oxidized in both proteomes, and additional protein oxidation and nitration was detected in one of the two proteomes. Detailed analyses of these post-translational modifications are presented. The proteins identified here significantly expand the known P. vivax proteome and complexity of available host protein functionality underlying the host-parasite interactive biology, and reveal unsuspected oxidative modifications that may impact protein function. BIOLOGICAL SIGNIFICANCE: Plasmodium vivax malaria is a serious neglected disease, causing an estimated 80 to 300 million cases annually in 95 countries. Infection can result in significant morbidity and possible death. P. vivax, unlike the much better-studied Plasmodium falciparum species, cannot be grown in long-term culture, has a dormant form in the liver called the hypnozoite stage, has a reticulocyte host-cell preference in the blood, and creates caveolae vesicle complexes at the surface of the infected reticulocyte membranes. Studies of stage-specific P. vivax expressed proteomes have been limited in scope and focused mainly on pathogen proteins, thus limiting understanding of the biology of this pathogen and its host interactions. Here three P. vivax proteomes are reported from biological replicates based on purified trophozoite-infected reticulocytes from different Saimiri boliviensis infections (the main non-human primate experimental model for P. vivax biology and pathogenesis). An in-depth analysis of two of the proteomes using 2D LC/MS/MS and multiple search engines identified 1375 pathogen proteins and 3209 host proteins. Numerous functional categories of both host and pathogen proteins were identified, including several known P. vivax protein family members (e.g., PHIST, eTRAMP and VIR), and 33% of protein identifications were classified as hypothetical. Ribosome subunit proteins were noted for both P. vivax and S. boliviensis, consistent with this parasite species' known reticulocyte host-cell specificity. In two biological replicates analyzed for post-translational modifications, hemoglobin was extensively oxidized, and various other proteins were also oxidized or nitrated in one of the two replicates. The cause of such protein modification remains to be determined but could include oxidized heme and oxygen radicals released from the infected red blood cell's parasite-induced acidic digestive vacuoles. In any case, the data suggests the presence of distinct infection-specific conditions whereby both the pathogen and host infected red blood cell proteins may be subject to significant oxidative stress.

Indexed as

Host-Pathogen InteractionsAnimalsHumansPlasmodium vivaxProteomeProtozoan ProteinsSaimiriTrophozoitesProteomeProtozoan ProteinsInfected red blood cellMalariaPlasmodium vivaxProtein oxidation/nitrationProteomicsTrophozoite stage

Identifiers

PMID25545414
PMCPMC4436379
OpenAlexW2008522889

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.